<--- Back to Details
First PageDocument Content
Medicine / Bristol-Myers Squibb / Fixed dose combination / Organofluorides / Cyclopropanes / Antiretroviral drug / Abacavir / Tenofovir / Reverse-transcriptase inhibitor / Chemistry / Organic chemistry / Purines
Medicine
Bristol-Myers Squibb
Fixed dose combination
Organofluorides
Cyclopropanes
Antiretroviral drug
Abacavir
Tenofovir
Reverse-transcriptase inhibitor
Chemistry
Organic chemistry
Purines

US Jemsek Dear HCP Letter FINAL DRAFT2.PDF

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 29,82 KB

Share Document on Facebook

Similar Documents

A Day in Life at BMS Welcome to A Day in Life at BMS where you will meet leaders from our R&D organization and learn more about research and development at Bristol-Myers Squibb, as well as network with our scientists. To

DocID: 1vrK6 - View Document

NoIN THE Supreme Court of the United States BRISTOL-MYERS SQUIBB COMPANY, PETITIONER,

DocID: 1tuCc - View Document

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty)

DocID: 1tut4 - View Document

September 2003 USA Bristol-Myers Squibb Medical Imaging

DocID: 1sKnx - View Document

May 2003 Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, Massachusetts 01862

DocID: 1sC8T - View Document